Inhibition of neutrophil migration at the site of infection increases remote organ neutrophil sequestration and injury.
Up-regulation of the leukocyte beta 2 integrin, CD18, is a key event in neutrophil-endothelial adhesion and neutrophil-mediated organ injury. Inhibition of CD18 with monoclonal antibodies reduces lung and liver neutrophil sequestration in animal models of Gram-negative bacteremia or endotoxemia. However, with a persistent septic challenge, interference with host leukocyte phagocytic defense could adversely affect outcome. To assess the effects of inhibiting CD18 on organ neutrophil responses, bacteremia, and organ injury after fecal peritonitis, mice underwent cecal ligation and puncture (CLP). At the time of CLP and 12 h later, mice received intravenous anti-CD18 antibody or control IgG. At 3, 6, and 18 h after CLP, lung and liver tissue neutrophil content were measured by myeloperoxidase (MPO) assay, peritoneal cells and blood leukocytes were differentially counted, blood was cultured, and serum aspartate aminotransferase was measured. There was a significant reduction in peritoneal neutrophil migration and an increase in blood neutrophils after anti-CD18 treatment compared with results from treatment with the control antibody. In the anti-CD18-treated group, liver MPO was increased fivefold at 6 and 18 h, while lung MPO was increased two-fold at 18 h when compared with the control antibody-treated group. The anti-CD18-treated group also had an increase in bacteria cultured from the blood at 6 and 18 h and an increase in serum aminotransferase at 18 h. Our data demonstrate that peritoneal neutrophil migration in response to an endogenous fecal challenge is CD18-dependent, and that this mechanism forms a vital part of host defense. Inhibition of CD18 increased neutrophil sequestration in the liver and lung and increased liver injury. This study demonstrates a paradoxical increase in organ neutrophil sequestration using a leukocyte anti-adhesion therapy during sepsis and suggests that anti-adhesion therapies targeted towards neutrophil may worsen outcome if given during an ongoing, localized infection.
Mercer-Jones
M A
MA
Department of Surgery, University of Louisville School of Medicine, Kentucky 40292, USA.
Heinzelmann
M
M
Peyton
J C
JC
Wickel
D
D
Cook
M
M
Cheadle
W G
WG
D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D001219:Aspartate Aminotransferases / Q000097:blood / Q000187:drug effects; D001769:Blood / Q000382:microbiology; D018821:CD18 Antigens / Q000187:drug effects / Q000378:metabolism*; D002432:Cecum / Q000601:surgery; D002465:Cell Movement; D004195:Disease Models, Animal; D005243:Feces; D007958:Leukocyte Count / Q000187:drug effects; D008026:Ligation; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D008168:Lung / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D016177:Macrophage-1 Antigen / Q000187:drug effects; D008297:Male; D051379:Mice; D009504:Neutrophils / Q000502:physiology*; D010529:Peritoneal Cavity / Q000473:pathology; D010538:Peritonitis / Q000503:physiopathology; D009195:Peroxidase / Q000187:drug effects / Q000378:metabolism
D000906:Antibodies; D018821:CD18 Antigens; D016177:Macrophage-1 Antigen; D009195:Peroxidase; D001219:Aspartate Aminotransferases